Journal: International Journal of Molecular and Cellular Medicine

Article Title: Sesamin Acts as Anti-leukemic Compound Interacting with Novel Phosphoprotein Targets and Inducing Apoptosis in Leukemic Cells

doi: 10.22088/IJMCM.BUMS.11.1.1

Figure Lengend Snippet: Cytotoxic effects of sesamin on (a) MOLT-4 and (b) NB4 cell line after 24 hour and 48 hour treatments compare with PBMC cells after 48 hour treatment. The results showed the percentage of cell inhibition measured by MTT assay. IC 50 at 48 hours for MOLT-4 and NB4 were reported as 104.84 and 121.00 µg/mL, respectively. Data were expressed as the mean±SD of independently three experiments. The differences between sesamin treated and untreated were examined for the statistical significance: *, p < 0.05; **, p < 0.01; ***, p < 0.001

Article Snippet: Leukemic Cell culture Acute lymphoblastic leukemia (ALL) MOLT-4 and acute promyelocytic leukemia (AML) NB4 cells purchased from Cell Lines Service GmbH (Eppelheim, Germany) were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin supplements in RPMI-1640 medium at the condition of 37 o C and 5% CO 2 .

Techniques: Inhibition, MTT Assay

Journal: International Journal of Molecular and Cellular Medicine

Article Title: Sesamin Acts as Anti-leukemic Compound Interacting with Novel Phosphoprotein Targets and Inducing Apoptosis in Leukemic Cells

doi: 10.22088/IJMCM.BUMS.11.1.1

Figure Lengend Snippet: The relative normalized expression of apoptotic genes in (a) MOLT-4 and (b) NB4 after sesamin treatment at IC 50 values of 100 and 120 µg/mL, respectively, for 48 hours. The experiment was determined by Real-time PCR. Data were expressed as the mean±SEM of three independent experiments. The differences between sesamin treated and untreated were examined for the statistical significance: *, p < 0.05; **, p < 0.01

Article Snippet: Leukemic Cell culture Acute lymphoblastic leukemia (ALL) MOLT-4 and acute promyelocytic leukemia (AML) NB4 cells purchased from Cell Lines Service GmbH (Eppelheim, Germany) were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin supplements in RPMI-1640 medium at the condition of 37 o C and 5% CO 2 .

Techniques: Expressing, Real-time Polymerase Chain Reaction

Journal: International Journal of Molecular and Cellular Medicine

Article Title: Sesamin Acts as Anti-leukemic Compound Interacting with Novel Phosphoprotein Targets and Inducing Apoptosis in Leukemic Cells

doi: 10.22088/IJMCM.BUMS.11.1.1

Figure Lengend Snippet: Venn diagram shows a set of 14 phosphoproteins present only in sesamin treated MOLT-4 (blue) and a different set of 14 phosphoproteins present only in sesamin treated NB4 (yellow)

Article Snippet: Leukemic Cell culture Acute lymphoblastic leukemia (ALL) MOLT-4 and acute promyelocytic leukemia (AML) NB4 cells purchased from Cell Lines Service GmbH (Eppelheim, Germany) were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin supplements in RPMI-1640 medium at the condition of 37 o C and 5% CO 2 .

Techniques:

Journal: International Journal of Molecular and Cellular Medicine

Article Title: Sesamin Acts as Anti-leukemic Compound Interacting with Novel Phosphoprotein Targets and Inducing Apoptosis in Leukemic Cells

doi: 10.22088/IJMCM.BUMS.11.1.1

Figure Lengend Snippet: Heatmap of phosphoproteins with significant difference in expression of (A) MOLT-4 and (B) NB4 treated with sesamin in various times compare with the control. The color indicates the expression level from low (green) to high (red). The blue arrow indicates the selected phosphoproteins

Article Snippet: Leukemic Cell culture Acute lymphoblastic leukemia (ALL) MOLT-4 and acute promyelocytic leukemia (AML) NB4 cells purchased from Cell Lines Service GmbH (Eppelheim, Germany) were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin supplements in RPMI-1640 medium at the condition of 37 o C and 5% CO 2 .

Techniques: Expressing

Journal: International Journal of Molecular and Cellular Medicine

Article Title: Sesamin Acts as Anti-leukemic Compound Interacting with Novel Phosphoprotein Targets and Inducing Apoptosis in Leukemic Cells

doi: 10.22088/IJMCM.BUMS.11.1.1

Figure Lengend Snippet: The schematic diagram shows the interactions between sesamin, caspase-3 (CASP3), caspase-7 (CASP7), caspase-8 (CASP8), caspase-9 (CASP9), BCL-2, and selected phosphoprotein; PARP4 and IPPK, in MOLT-4 and NB4 leukemic cell lines using STITCH database. The round shape represents protein. The oval shape represents chemical. Red circle indicates selective proteins. Red dashed circle indicates selective chemicals

Article Snippet: Leukemic Cell culture Acute lymphoblastic leukemia (ALL) MOLT-4 and acute promyelocytic leukemia (AML) NB4 cells purchased from Cell Lines Service GmbH (Eppelheim, Germany) were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin supplements in RPMI-1640 medium at the condition of 37 o C and 5% CO 2 .

Techniques:

Journal: Experimental and Therapeutic Medicine

Article Title: Tumor Treating Fields modulate apoptotic and immune programs in T-cell acute lymphoblastic leukemia cell lines

doi: 10.3892/etm.2026.13195

Figure Lengend Snippet: TTFields reduce viability of T-cell acute lymphoblastic leukemia cells in an intensity- and time-dependent manner. (A) Normalized cell viability of Jurkat (black) and MOLT-4 (gray) cells after exposure to 0.0-1.2 V/cm TTFields. Jurkat exhibits minimal change at 0.4 V/cm but sharp reductions at ≥0.8 V/cm; MOLT-4 declines across all intensities. The right panel shows cell viability across the tested frequency range, with no marked frequency-dependent differences observed. (B) Time-course of live-cell counts (0-96 h) under control vs. TTFields. Error bars represent the mean ± SD of three independent experiments. * P<0.05, ** P<0.01 and *** P<0.001. TTFields/TTF, Tumor Treating Fields.

Article Snippet: Human T-ALL cell lines, Jurkat (cat. no. 40152) and MOLT-4 (cat. no. 21582), were obtained from the Korean Cell Line Bank.

Techniques: Control

Journal: Experimental and Therapeutic Medicine

Article Title: Tumor Treating Fields modulate apoptotic and immune programs in T-cell acute lymphoblastic leukemia cell lines

doi: 10.3892/etm.2026.13195

Figure Lengend Snippet: TTFields increase cellular granularity and mitochondrial fluorescence in T-cell acute lymphoblastic leukemia cell lines. (A) Representative FSC/SSC plots and quantification of side-scatter mean fluorescence intensity (median SSC-A values). FSC-A associates with cell size, while SSC-A reflects intracellular complexity such as organelle content and granularity. (B) MitoTracker green fluorescence intensity was normalized to control values and was significantly elevated in both Jurkat and MOLT-4 cells following TTFields treatment. (C) Intracellular ATP levels measured using the CellTiter-Glo luminescence assay and normalized to control values. Data are presented as the mean ± SD from three independent experiments. * P<0.05, ** P<0.01 and *** P<0.001. TTFields/TTF, Tumor Treating Fields; SSC, side scatter; FSC, forward scatter; A, area; CON, control; MFI, mean fluorescence intensity; a.u., arbitrary units.

Article Snippet: Human T-ALL cell lines, Jurkat (cat. no. 40152) and MOLT-4 (cat. no. 21582), were obtained from the Korean Cell Line Bank.

Techniques: Fluorescence, Control, Luminescence Assay

Journal: Experimental and Therapeutic Medicine

Article Title: Tumor Treating Fields modulate apoptotic and immune programs in T-cell acute lymphoblastic leukemia cell lines

doi: 10.3892/etm.2026.13195

Figure Lengend Snippet: TTFields reduce CD69 expression and alter immune-related gene transcription in T-cell acute lymphoblastic leukemia cells. (A) Flow-cytometric analysis showed reduced CD69 + fractions in pre-activated Jurkat and MOLT-4 cells following 48-96 h TTFields exposure, with quantitative summaries indicating a consistent downward trend. TTFields treatment reduced CD69 expression in MOLT-4 cells, whereas no significant change was observed in Jurkat cells. (B) Gene-expression profiling after 48 h further demonstrated decreased CD69 and IL-2 and increased RELA and CBLB transcripts. Data represent the mean ± SD from three independent experiments. * P<0.05, ** P<0.01 and *** P<0.001. TTFields/TTF, Tumor Treating Fields; RELA, RELA proto-oncogene, NF-κB subunit; CBLB, CBL proto-oncogene B; Con, control.

Article Snippet: Human T-ALL cell lines, Jurkat (cat. no. 40152) and MOLT-4 (cat. no. 21582), were obtained from the Korean Cell Line Bank.

Techniques: Expressing, Gene Expression, Control